Induction immunosuppression in liver transplantation: A review

Transplant International

Volumn 26, Issue 7, 2013, Pages 673-683

  Turner, Alexandra P ^a   Knechtle, Stuart J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti IL 2R; anti lymphocyte globuline; immunosuppression clinical; liver clinical; pediatric transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADD ON THERAPY; AREA UNDER THE CURVE; CANCER MORTALITY; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; CYTOMEGALOVIRUS INFECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; CALCINEURIN; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RECURRENCE;

EID: 84879030505     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12100     Document Type: Review

References (71)

1. Kirk AD,. Induction immunosuppression. Transplantation 2006; 82: 593.
2. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D,. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
3. Cai J, Terasaki PI,. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of united network for organ sharing registry data. Transplantation 2010; 90: 1511.
4. Hanaway MJ, Woodle ES, Mulgaonkar S, et al,. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
5. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al,. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
6. Kovarik JM, Moore R, Wolf P, et al,. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999; 13: 32.
7. www.srtr.org/annual-reports/2010.
8. Boillot O, Seket B, Dumortier J, et al,. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009; 15: 1426.
9. Bogetti D, Sankary HN, Jarzembowski TM, et al,. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005; 19: 507.
10. Tchervenkov J, Flemming C, Guttmann RD, Gachons D,. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transpl Proc, 1997; 29: 13S.
11. Wang XF, Li JD, Peng Y, Dai Y, Shi, G, Xu, W,. Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials. Transpl Proc 2010; 42: 4567.
12. Neuhaus P, Clavien PA, Kittur D, et al,. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132.
13. Gruttadauria S, Cintorino D, Piazza T, et al,. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. Transpl Proc 2006; 38: 1106.
14. Sato K, Sekiguchi S, Kawagishi N, et al,. Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy. Clin Transplant 2011; 25: 61.
15. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR,. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transpl Proc 2006; 38: 3633.
16. Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C,. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transpl Proc 2005; 37: 1151.
17. Tryphonopoulos P, Madariaga JR, Kato T, et al,. The impact of Campath 1H induction in adult liver allotransplantation. Transpl Proc 2005; 37: 1203.
18. Tzakis AG, Tryphonopoulos P, Kato T, et al,. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209.
19. Kato T, Selvaggi G, Panagiotis T, et al,. Pediatric liver transplant with Campath 1H induction-preliminary report. Transpl Proc 2006; 38: 3609.
20. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med, 1994; 331: 1110.
21. Morard I, Mentha G, Spahr L, et al,. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006; 20: 96.
22. Wilkinson A, Pham PT,. Kidney dysfunction in the recipients of liver transplants. Liver Transpl, 2005; 11 (11 Suppl 2): S47.
23. Gonwa TA, Mai ML, Melton LB, et al,. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934.
24. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
25. Cohen AJ, Stegall MD, Rosen CB, et al,. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8: 916.
26. Emre S, Gondolesi G, Polat K, et al,. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7: 220.
27. Eckhoff DE, McGuire B, Sellers M, et al,. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867.
28. Heffron TG, Smallwood GA, Pillen T, et al,. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transpl Proc 2002; 34: 1514.
29. Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE,. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation 2004; 78: 1212.
30. Neuberger JM, Mamelok RD, Neuhaus P, et al,. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327.
31. Yoshida EM, Marotta PJ, Greig PD, et al,. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl, 2005; 11: 1064.
32. Calmus Y, Kamar N, Gugenheim J, et al,. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010; 89: 1504.
33. Borobia AM, Romero I, Jimenez C, et al,. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436.
34. Andres A, Budde K, Clavien PA, et al,. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation 2009; 88: 1101.
35. Barraclough KA, Staatz CE, Johnson DW, et al,. Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 2012; 25: 1182.
36. Starzl TE, Murase N, Abu-Elmagd K, et al,. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
37. De Ruvo N, Cucchetti A, Lauro A, et al,. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8.
38. Benitez CE, Puig-Pey I, Lopez M, et al,. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10: 2296.
39. Donckier V, Craciun L, Lucidi V, et al,. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. Transplantation 2009; 87 (9 Suppl): S91.
40. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE,. Tolerance: is it worth the risk? Transplantation 2005; 79: 1157.
41. Soliman T, Hetz H, Burghuber C, et al,. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13: 1039.
42. Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P,. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transpl Proc 2004; 36: 1747.
43. Bajjoka I, Hsaiky L, Brown K, Abouljoud M., Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008; 14: 66.
44. Segev DL, Sozio SM, Shin EJ, et al,. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512.
45. Teixeira R, Pastacaldi S, Papatheodoridis GV, Burroughs AK,. Recurrent hepatitis C after liver transplantation. J Med Virol 2000; 61: 443.
46. Eason JD, Blazek J, Mason A, Nair S, Loss GE., Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transpl Proc 2001; 33: 1470.
47. Pageaux GP, Calmus Y, Boillot O, et al,. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004; 10: 1454.
48. Neumann UP, Berg T, Bahra M, et al,. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
49. Llado L, Fabregat J, Castellote J, et al,. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14: 1752.
50. Llado L, Xiol X, Figueras J, et al,. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44: 710.
51. Boillot O, Mayer DA, Boudjema K, et al,. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61.
52. Otero A, Varo E, de Urbina JO, et al,. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009; 15: 1542.
53. Klintmalm GB, Washburn WK, Rudich SM, et al,. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521.
54. Filipponi F, Callea F, Salizzoni M, et al,. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488.
55. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O,. Review article: use of induction therapy in liver transplantation. Transplant Rev 2012; 26: 246.
56. Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M., Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl 2011; 17: 32.
57. Marcos A, Eghtesad B, Fung JJ, et al,. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966.
58. Herrero JI, Lorenzo M, Quiroga J, et al,. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005; 11: 89.
59. Fernberg P, Edgren G, Adami J, et al,. Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. Am J Transplant 2011; 11: 2472.
60. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K., Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
61. Becker T, Foltys D, Bilbao I, et al,. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 2008; 86: 1689.
62. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G., Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90: 1562.
63. Schmeding M, Sauer IM, Kiessling A, et al,. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007; 12: 15.
64. Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A., Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011; 54: 541.
65. Liu CL, Fan ST, Lo CM, et al,. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004; 10: 728.
66. Schnitzbauer AA, Doenecke A, Sothmann JL, et al,. Improved outcome after 'bottom-up' immunosuppression in liver transplant recipients with preoperative renal impairment. Eur Surg Res 2010; 45: 356.
67. Schnitzbauer AA, Scherer MN, Rochon J, et al,. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study. BMC Nephrol 2010; 11: 24.
68. www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf.
69. Gras JM, Gerkens S, Beguin C, et al,. Steroid-free, tacrolimus- basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008; 14: 469.
70. Spada M, Petz W, Bertani A, et al,. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006; 6: 1913.
71. Kerkar N, Morotti RA, Iyer K, et al,. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients. Clin Transplant 2011; 25: E584.